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ABSTRACT
Introduction: Dementia and mild cognitive
impairment are associated with an increased risk of
depression, anxiety, psychological distress and poor
mental health-related quality of life. However, there is
a lack of research examining the evidence base for
psychological interventions targeting general
psychological well-being within this population.
Furthermore, there is little research relating to the
design of randomised controlled trials examining
psychological interventions for dementia and mild
cognitive impairment, such as effective recruitment
techniques, trial eligibility and appropriate
comparators.
Methods and analysis: Systematic review of
electronic databases (CINAHL; EMBASE; PsychInfo;
MEDLINE; ASSIA and CENTRAL), supplemented by
expert contact, reference and citation checking, and
grey literature searches. Published and unpublished
studies will be eligible for inclusion with no limitations
placed on year of publication. Primary outcomes of
interest will be standardised measurements of
depression, anxiety, psychological distress or mental
health-related quality of life. Eligibility and
randomisation proportions will be calculated as
secondary outcomes. If data permits, meta-analytical
techniques will examine: (1) overall effectiveness of
psychological interventions for people with dementia or
mild cognitive impairment in relation to outcomes of
depression, anxiety, psychological distress or mental
health-related quality of life; (2) clinical and
methodological moderators associated with
effectiveness; (3) proportions eligible, recruited and
randomised.
Ethics and dissemination: Ethical approval is not
required for the present systematic review. Results will
inform the design of a feasibility study examining a
new psychological intervention for people with
dementia and depression, with dissemination through
publication in peer-reviewed journals and presentations
at relevant conferences.
Trial registration number: CRD42015025177.
INTRODUCTION
While healthcare advances across the devel-
oped world have resulted in increased life
expectancy,1 increased numbers of people
are also placed at risk of developing chronic
health conditions.2 As such, dementia, a
common chronic condition associated with
ageing,3 has become of signiﬁcant concern.
Current estimates of people living with
dementia worldwide are in excess of 35
million, set to double by 2030, and more
Strengths and limitations of this study
▪ Review protocol adopts the following quality
standards—independent study selection, data
extraction, risk of bias assessments by two
researchers—as informed by the Centre of
Reviews and Dissemination guidance and
PRISMA-P guidelines.
▪ The first review to be conducted with a second-
ary aim of examining factors related to success-
ful participant recruitment into psychological
interventions trials for dementia and mild cogni-
tive impairment.
▪ To increase quality of included studies and
reduce methodological heterogeneity, studies
with high risk of bias (following Cochrane
Collaboration guidance) concerning method of
random sequence generation and allocation con-
cealment were excluded.
▪ Owing to resource limitations, selected studies
were limited to those publically available in the
English language; therefore, language bias may
be present.
▪ High levels of clinical heterogeneity may exist as
a consequence of included studies adopting psy-
chological interventions informed by a variety of
psychological approaches and including partici-
pants with different dementia types and levels of
cognitive impairment.
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than triple by 2050.4 In the absence of a cure for
dementia, or identiﬁcation of speciﬁc causal factors as
targets for preventative interventions,5 dementia care
strategies are focused on providing appropriate psycho-
logical and psychosocial support, alongside the provision
of physical care.6 However, access to evidence-based psy-
chological therapies to improve the long-term psycho-
logical well-being and mental health-related quality of
life in people with dementia is currently limited.7
Elevated symptoms of depression in people with
dementia are common with prevalence reported to be
as high as 308 9–50%,10 compared to 13.2% of older
adults without cognitive impairment.11 However, the
prevalence of depression in people with dementia
should potentially be considered with caution. Rates of
depression may vary across dementia type, with a small
number of studies indicating prevalence rates higher in
patients experiencing dementia with Lewy bodies and
vascular dementia, in comparison with Alzheimer’s
disease.8 Large variations in rates of depression in
Alzheimer’s disease have also been found when a stricter
criterion is adopted with respect to meeting a diagnosis
of major depression.12 Studies adopting International
Classiﬁcation of Diseases (ICD) 10 criteria have found
rates of 513–14% using DSM-IV criteria,14 and 3815–
44%14 when using the National Institutes of Mental
Health (NIMH) proposed standardised diagnostic cri-
teria for depression in Alzheimer’s disease.16 Such wide
variations in prevalence rates may be due to the differ-
ences in depressive symptom presentation in people
with dementia and variation diagnostic criterion used in
these tools.12 In relation to mild cognitive impairment
(MCI) rates of mild depressive symptoms have varied
from 26.5%17 to 49.3%,18 with 14% experiencing severe
depressive symptoms.18 Furthermore, prevalence of ele-
vated symptoms of anxiety have been found to range
from 8% to 71%,19 with 5–21% of people with a demen-
tia meeting diagnostic criteria for a speciﬁc anxiety dis-
order.20 However, there is little consensus concerning
how to deﬁne and measure anxiety experienced by
people with a dementia.9 Rates of anxiety symptoms
have also been found to vary widely in MCI (10–74%).21
Despite variability reported regarding the prevalence
of depression and anxiety in people with dementia and
MCI,9 12 a clear need remains for evidence-based psy-
chological therapies to address these difﬁculties.
However, only six studies were identiﬁed in a Cochrane
review examining the effectiveness of psychological inter-
ventions speciﬁcally targeting depression or anxiety.9
Other reviews have tended to focus on the effectiveness
of non-pharmacological interventions for a variety of
neuropsychiatric symptoms in severe or very severe
dementia.22 Furthermore, while depression and anxiety
have a signiﬁcant impact on the lives of people with
dementia and MCI, the negative impact of these psycho-
logical difﬁculties extend beyond their symptomatology
alone.8 For depression and anxiety, symptoms have been
associated with reduced quality of life,8 23 increased
likelihood of being placed in a nursing home or other
institution,24 25 and caregiver burden.26 27 Furthermore,
speciﬁcally with respect to depression, higher rates of
cognitive decline have been reported,28 with increased
behavioural disturbances associated with anxiety.29
As such, the need to develop evidence-based psycho-
logical interventions to support the long-term emotional
needs of people experiencing dementia, and examine
their impact on difﬁculties beyond those related solely
with depression and anxiety, is justiﬁed. Developing
interventions that enable people with dementia to ‘live
well’ is a priority with the UK National Dementia strat-
egy,30 with recent research focusing on improving
general well-being and quality of life to facilitate people
to ‘live well’ with dementia.31 However, research on
dementia has previously adopted a disease-focused
model, rather than a focus on longer term well-being
and quality of life.32 Indeed, a limitation of existing lit-
erature is that interventions tend to overlook outcomes
relating to quality of life and general psychological well-
being.33 This is of particular importance considering the
elevated stigma associated with mental health difﬁculties
in older adult physical health populations,34 and asso-
ciated low levels of help-seeking regarding mental
health support.35 36 One reason for low levels of help-
seeking behaviour may relate to the greater identiﬁca-
tion of physical health populations with the experience
of general distress as a response to illness,37 as opposed
to a speciﬁc mental health difﬁculty, such as depression
or anxiety. Subsequently, previous reviews focusing on
interventions targeting medicalised constructs, such as
depression or anxiety,9 may have omitted the evidence
base concerning psychological interventions targeting
broader constructs relating to general psychological dis-
tress and well-being.
Currently, there are no systematic reviews examining
the evidence base of psychological interventions tar-
geted at improving general psychological well-being or
mental health-related quality of life in people with
dementia and MCI.38 While a recent review9 has exam-
ined the effectiveness of psychological interventions for
people with dementia and MCI targeting depression
and anxiety, this current review protocol widens the
scope by also including interventions targeting general
psychological distress and quality of life. Further, results
of this review will allow the independent triangulation of
results obtained by this previous review.9
As well as establishing the evidence base for psycho-
logical interventions targeting general psychological
well-being in people with dementia or MCI, it may also
be prudent to investigate clinical and methodological
characteristics associated with these studies. A number
of complexities have been identiﬁed when recruiting
participants into pharmaceutical trials associated with
dementia or MCI, including capacity to consent, and
the presence of physical or neuropsychiatric symptoms
impacting on eligibility.38 Furthermore, a number of
known barriers exist regarding recruiting older adults
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into psychological intervention trials, including stigma
concerning mental health difﬁculties experienced by
older adults,39–41 preoccupation with physical health
symptoms,42 and lack of healthcare professional recogni-
tion.43 Participants and professionals have also been
found to view participation in depression trials with
greater caution for older rather than younger adults,
and for people with physical health conditions.44 With
respect to anxiety, symptoms are frequently unrecog-
nised in older adults, given they often do not conform
to existing diagnostic criteria.45 Additionally, elevated
stigma exists concerning anxiety in older adults in com-
parison with other mental health conditions, including
depression.41
Greater understanding of methodological factors may,
therefore, help inform successful recruitment strategies
into subsequent studies aiming to examine the effective-
ness of psychological interventions for people with
dementia and MCI to improve psychological well-being.
A recent systematic review examining recruitment in
pharmacological trails for Alzheimer’s disease has sug-
gested 10% of potential participants would take part in
clinical drug trials if all those diagnosed were invited to
participate.38 However, currently, no reviews exist exam-
ining factors related to successful recruitment into psy-
chological interventions for dementia. The present
systematic review, therefore, aims to identify clinical and
methodological moderators associated with effectiveness
and recruitment strategies for trials involving people
with dementia and MCI, alongside examining the
overall effectiveness of psychological interventions to
improve psychological well-being.
OBJECTIVES
1. To examine the effectiveness of psychological inter-
ventions targeted at improving psychological and
emotional well-being and mental health-related
quality of life, compared with active and inactive
control conditions, in adults with dementia or MCI.
2. To investigate clinical and methodological modera-
tors associated with effectiveness.
3. To identify recruitment techniques and effectiveness
of the techniques used across trials.
METHODS AND ANALYSIS
The Centre of Reviews and Dissemination (CRD) guid-
ance for conducting systematic reviews,46 will be fol-
lowed, with results of the review reported in accordance
with PRISMA-P guidelines.47 The review is registered
with the PROSPERO International Prospective
Register of Systematic Reviews (registration number
CRD42015025177).
Study inclusion and exclusion criteria
Type of studies
Randomised controlled trials (RCTs) and cluster RCTs,
using a method of random sequence generation with
allocation concealment assessed as having low or
unclear risk of bias using the Cochrane Collaboration
Risk of Bias tool,48 will be eligible for inclusion. This is
to help minimise the inclusion of studies of low quality
with high of selection bias known to inﬂate effect
sizes49 50 and is a technique used in a number of other
systematic reviews and meta-analyses.51–53 Quasi-RCTs
and cross-over trials will not be eligible for inclusion.
Types of participants
Adults with diagnosis of a dementia by the Diagnostic
and Statistical Manual of Mental Disorders (DSM) IV or
DSM-5 (American Psychiatric Association (APA54 55)
ICD-1056 alternative validated diagnostic criteria, or
recorded in their medical records. Alzheimer’s disease,
vascular dementia, dementia with Lewy bodies and fron-
totemporal dementia and will be eligible for inclusion.
In addition, adults with a diagnosis of MCI, a term used
to describe a person experiencing problems with cogni-
tive function, but with such difﬁculties not being severe
enough to currently attract a diagnosis of dementia, will
be eligible for inclusion. Valid methods of diagnosis
adopted for MCI will include: DSM-5 criteria,55
Petersen’s criteria (P-MCI,57), alternative validated diag-
nostic criteria, or where recorded in medical records.
No limitations will be placed on the severity of demen-
tia, length of time since diagnosis, with dementia
patients in community and institutional settings eligible.
No restrictions will be placed on severity of depression,
anxiety, psychological distress or mental health-related
quality of life.
Types of interventions
The review will include any psychological therapy and
includes speciﬁc interventions with no limitations placed
on the psychological therapy model informing the inter-
vention. Psychological therapies eligible for inclusion
will use speciﬁc therapeutic principles and techniques
hypothesised to target an improvement in psychological
well-being or a reduction in symptoms associated with
psychological difﬁculties. Psychological therapies eligible
for inclusion may include, but is not restricted to: cogni-
tive–behavioural therapies; behavioural interventions;
social skills training; relaxation therapy; psychodynamic;
humanistic/counselling approaches; and interpersonal
therapies. The intervention should target an improve-
ment in general psychological well-being as identiﬁed by
measurement of depression, anxiety, psychological dis-
tress or mental health-related quality of life. As long as
the intervention is targeted at improving psychological
well-being in the person with dementia or MCI, dyadic
interventions that may additionally target the informal
carer will also be eligible. Additionally, all intervention
delivery modes (individual, group or dyadic) and
methods of support (face to face, telephone, internet)
will be eligible for inclusion. There will be no limitations
placed on the professional background of the person
supporting the intervention; additionally unsupported
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(self-guided/self-administered) interventions will also be
eligible for inclusion.
Both inactive and active comparators will be consid-
ered eligible. However, the trial design must allow for
the isolation of the effect of the psychological interven-
tion of interest. Examples of appropriate designs are as
follows:
1. Psychological intervention versus control
(no-treatment control; wait-list control; treatment as
usual);
2. Psychological intervention versus non-speciﬁc factor
component control,58 (eg, where therapist time is
equivalent to that provided in the experimental arm
but only non-speciﬁc factors are provided as an
intervention);
3. Psychological intervention plus medication versus
medication;
4. Psychological intervention plus information versus
information.
Types of settings
There will be no restriction placed on setting of inter-
vention delivery. For example, studies where the inter-
vention was delivered in primary care, secondary care,
university-based clinics, homes, residential care homes
and community settings will all be included.
Types of outcome measures
Studies eligible for inclusion will use one or more of the
following self-report, clinician or proxy administered
primary outcome measurements: (1) standardised meas-
urement of depression (eg, the Beck Depression
Inventory, BDI-II,59); (2) standardised measurement of
anxiety, (eg, the Beck Anxiety Inventory, BAI60); (3)
standardised measurement of psychological distress,
deﬁned as a measurement of general psychiatric distress
including domains of mental health-related symptoms
such as depression, anxiety, insomnia and somatic symp-
toms (eg, the General Health Questionnaire, GHQ61);
or (4) standardised measurement of quality of life if
they include a mental health-speciﬁc subscale or
domain (eg, the SF-3662) or the Alzheimer
disease-related quality of life (ADRQL63). Where mul-
tiple time points are reported, a primary end point
≤6 months post-treatment will be adopted to minimise
the likelihood bias associated with examining short-term
post-treatment effects only that are likely to result in
higher effect sizes.64 51 65 However, outcomes for all
time points reported in the included studies will be
extracted to enable a potential moderator analysis on
length of follow-up.
Search methods for identification of studies
Electronic searches
The following electronic databases will be searched:
Cumulative Index to Nursing and Allied Health
Literature (CINAHL); Excerpta Medica DataBase
(EMBASE); PsychInfo; MEDLINE; Applied Social
Sciences Index and Abstracts (ASSIA) and the Cochrane
Central Register of Controlled Trials (CENTRAL). A
comprehensive search strategy was developed using
medical subject headings (MeSH). The Ovid MEDLINE
search strategy can be found in online supplementary
ﬁle 1. No limitations will be placed on year of publica-
tion, and only studies which are publically available in
the English language will be eligible for inclusion due to
limited resources to funding translation services.
Searching other resources
The reference lists and citations of all included studies
will be hand searched for further eligible studies. In
addition, journals containing the highest numbers of
included studies will be hand searched for recent poten-
tially eligible publications (≤12 months). Experts in the
ﬁeld will also be contacted to identify any unpublished
or ongoing trials.
Data collection and analysis
Selection of studies
Two researchers will act as reviewers and screen titles
and abstracts. Full paper reviews will be conducted inde-
pendently to determine inclusion with all discrepancies
initially discussed. If consensus cannot be reached, a
third member of the research team (PF) will be con-
tacted. An Excel spreadsheet has been developed to
manage all review data.
Data extraction and management
Following guidance,46 data will be double extracted by
the two reviewers ( JW and MA) using a data extraction
form developed in Excel for this review, with discrepan-
cies discussed and the third member of the review team
(PF) contacted if consensus is not reached. Study
characteristics will be extracted from published papers,
with study authors contacted in the event of missing
data. In addition to the extraction of standard study
information (study identiﬁcation features, study
characteristics, primary outcome measurements, statis-
tical approaches and primary results) the following
information will also be extracted:
1. Participant characteristics: dementia subtype (eg,
Alzheimer’s disease, vascular dementia, dementia
with Lewy bodies, frontotemporal dementia, MCI);
how diagnosis of dementia or MCI was established
(eg, patient record check or in-trial procedures; vali-
dated diagnostic tool for dementia used (eg, DSM-IV,
DSM-V or ICD-10); global severity of dementia; sever-
ity of cognitive impairment; severity of behavioural
and psychological symptoms of dementia; time since
diagnosis; physical health comorbidities; neuropsychi-
atric comorbidities; age; gender; ethnicity; educa-
tional status; support from an informal carer (yes/
no).
2. Intervention characteristics: psychological model (eg,
cognitive therapy, behavioural therapy, interpersonal
therapy; psychoeducation; problem-solving;
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psychosocial support; relaxation); mode of delivery
(eg, individual, group, dyadic); type of support (eg,
face-to-face, telephone, email); treatment setting (eg,
community, care home, primary care, secondary
care); clinician delivering treatment; intervention-
speciﬁc training of clinicians delivering the treat-
ment; treatment duration; number of sessions; length
of sessions; manualised treatment and measurement
of treatment integrity.
3. Recruitment characteristics: patient or dyadic (patient
and carer); type of consent (eg, informed, proxy);
sampling method; recruitment setting (eg, clinical,
community, mixed); type of recruitment (eg,
mail-out, physician/healthcare professional referral,
advertisement); number of participants invited,
number of participants screened, number of partici-
pants eligible, number of participants randomised,
reasons for non-eligibility, whether respondent
characteristics match the target population deﬁned
as response rate ≥80% or appropriate analysis
comparing respondent and non-respondent
characteristics.38
4. Statistical approaches and primary results:
4.1 Consistent with the aims of intention-to-treat ana-
lysis, any outcome information available for patients
excluded from the original analysis will also be
extracted.
4.2 For cluster trials, estimates of intracluster correl-
ation coefﬁcients (ICC) and average cluster sizes will
be gathered, which are potentially needed for
revised analyses (see Unit of analysis issues section).
4.3 Within-study correlations between different out-
comes will be extracted, where available, to inform
on the simultaneous effects of treatment on the out-
comes of interest in the same participants.
Assessment of risk of bias
The methodological quality of included studies will be
examined independently by the two reviewers using the
Cochrane Collaboration’s Risk of Bias tool.48 Study
quality ratings will be compared, discrepancies discussed,
and the third reviewer (PF) contacted if consensus is
not reached. Speciﬁcally, selection, performance, attri-
tion and reporting bias will be examined. Reporting bias
will be examined by making efforts to obtain study pro-
tocols (eg, obtaining published protocols, checking trial
databases or requesting from study authors) and com-
paring outcomes reported in the protocol with those
reported in the paper. Additionally, comparisons will be
made between outcomes reported in the methods and
results sections of trial reports. Study authors will be con-
tacted in the event of any discrepancy to identify poten-
tial changes to the study protocol and request any
missing data. For cluster-randomised trials, studies will
be examined for ‘unit-of-analysis’ errors,66 67 whereby
groups were randomised in the trial, but individuals
were treated as the randomised units in analysis. Cluster
trials will also be assessed for ‘recruitment bias’ in which
individuals are recruited after cluster randomisation,
with knowledge of cluster allocation.68
Data synthesis and statistical analysis
Measures of treatment effect
If available data permits, a meta-analysis will be con-
ducted using ‘metafor’ package in R.69 Hedges’ g will be
calculated to determine the post-treatment between-
group standardised mean effect size from outcomes
relating to depression, anxiety, psychological distress and
mental health-related quality of life separately. In cases
reporting multiple time points, the longest follow-up
time point will be adopted ≤6 months. Comparisons will
be analysed separately with control condition sample
size halved for studies where two treatments eligible for
inclusion are compared with one control condition.
Likewise, for studies comparing two control conditions
with one treatment condition, comparisons will be ana-
lysed separately with the sample size in the treatment
condition halved. A random effects model will be
adopted as wide variations in treatment, participant
characteristics and methodological factors are expected
between the studies.70 71
Unit of analysis issues
For cluster RCTs, if clustering was not appropriately con-
sidered in the original analysis, estimates of ICC and
average cluster sizes will be used to increase the SEs
appropriately.68 If the required information cannot be
obtained from source, authors will be contacted directly,
or values borrowed from similar studies if possible.
Summary proportions
To examine recruitment and data permitting, summary
proportions will be calculated.69 Effects will be reported
as proportions but transformed to log (odds) for the
purposes of the meta-analysis. Speciﬁcally, the following
proportions will be included:
1. Proportion of participants invited into the trials and
subsequently screened for eligibility.
2. Proportion of participants screened for eligibility in
the trials and subsequently found to be eligible for
inclusion.
3. Proportion of participants found eligible for study
and subsequently randomised into the trials.
Dealing with missing data
Missing means and SDs of post-treatment measurement
scores will be requested from authors. The intention-to-
treat principle will be followed as far as possible, analys-
ing all patients as they were randomised. Sensitivity ana-
lysis will be conducted by temporarily dropping studies
with high attrition in at least one arm (≥30%) from the
analysis.
Assessment of heterogeneity
The presence of statistically signiﬁcant heterogeneity will
be examined by calculating the Q statistic with the
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quantiﬁcation of the degree of heterogeneity calculated
using the I2 statistic.72 73 If substantial heterogeneity is
found (I2 value ≥50%), possible causes will be examined
through subgroup analyses.
Funnel asymmetry
To investigate sources of possible bias (publication bias,
language bias, inclusion of small studies with poor meth-
odological rigour, heterogeneity), funnel plot asymmetry
will be examined using Egger’s Test of the Intercept,74
where a minimum of 10 studies are included within the
analysis.75 Separate funnel plots will be calculated for
each of the main outcomes (depression, anxiety, psycho-
logical distress and mental health-related quality of life).
Effect sizes for each outcome will also be calculated
taking into account the potential of bias using the trim
and ﬁll procedure.76
Sensitivity analysis
Sensitivity analysis will be conducted by
1. Temporarily dropping small studies (n≤20 across
conditions).
2. Individually omitting each study from the
meta-analysis to examine whether the effect size was
biased by the inclusion of any particular study.
3. Selective outcome reporting bias,77 will be examined
using the maximum bias-bound approach,78 79 with
new treatment effects and CIs calculated by the add-
ition of the bias-bound value to the original pooled
effects.78 79
Moderator analysis
Moderator analysis will be undertaken to examine inter-
vention components, methodological components and
participant characteristics of studies associated with
effectiveness, when number of studies permits.
Speciﬁcally, the following moderators will be examined:
1. Dementia subtype;
2. Baseline severity of cognitive impairment;
3. Psychological model intervention based on;
4. Mode of delivery (eg, individual, dyadic or group);
5. Baseline severity of depression, anxiety, psychological
distress or mental health-related quality of life;
6. Treatment setting;
7. Recruitment setting;
8. Type of control condition;
9. Length of follow-up.
If sufﬁcient data are available, subgroup analysis, or
meta-regression67 will be conducted to examine modera-
tors. With heterogeneity being anticipated, random
effects will be adopted with Q and I2 reported as mea-
sures of heterogeneity. It should be noted that moder-
ator analysis only provides correlational, not casual,
data.80 Any signiﬁcant ﬁndings should be examined
through further primary research.81
DISCUSSION
Currently, there is no comprehensive review of psycho-
logical interventions for people with dementia or MCI
that systematically examines:
1. Several outcomes relating to psychological well-being,
such as depression, anxiety, mental health-related
quality of life and psychological distress.
2. The quality of the available evidence.
3. Effectiveness of recruitment strategies used.
4. Effectiveness and clinical and methodological compo-
nents associated with effectiveness.
This review will therefore examine the effectiveness of
psychological interventions targeting psychological well-
being for people experiencing dementia or MCI, iden-
tify clinical and methodological moderators of effect size
alongside strategies associated with successful recruit-
ment. With respect to these objectives, this review seeks
to meet important objectives within phase I of the
revised MRC guidance concerning the development of
complex interventions.82 It represents the ﬁrst step
towards developing a new psychological treatment for
difﬁculties with psychological well-being in people with
dementia, identifying important methodological uncer-
tainties (eg, successful recruitment methods; appropri-
ate comparator arms) to inform the design of a phase II
feasibility study.
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